Moleculin Biotech Inc Cash Flow Conversion Efficiency
Moleculin Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Moleculin Biotech Inc (MBRX) has a cash flow conversion efficiency ratio of -0.358x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.37 Million) by net assets ($15.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Moleculin Biotech Inc (2015–2025)
Cash flow conversion efficiency of Moleculin Biotech Inc from 2015 to 2025. This chart illustrates how Moleculin Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Moleculin Biotech Inc for real-time trading data and today's change.
Moleculin Biotech Inc Cash Flow Conversion Ratio Explained
Moleculin Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Moleculin Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Moleculin Biotech Inc ranked by their cash flow conversion efficiency. Also see MBRX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MONY Group plc
LSE:MONY
|
0.279x |
|
Park Ha Biological Technology Co., Ltd.
NASDAQ:PHH
|
-12.940x |
|
OXE Marine AB
ST:OXE
|
-0.326x |
|
Tong Hua Holding Public Company Limited
BK:TH
|
-0.006x |
|
PNC Technologies co. Ltd
KQ:237750
|
0.017x |
|
Telefast Indonesia
JK:TFAS
|
0.023x |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
0.024x |
|
Horizon Petroleum Ltd
V:HPL
|
0.257x |
Annual Cash Flow Conversion Efficiency for Moleculin Biotech Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of Moleculin Biotech Inc from 2015 to 2025. Review Moleculin Biotech Inc (MBRX) flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $15.01 Million | $-22.73 Million | -1.515x | +62.04% |
| 2024-12-31 | $5.98 Million | $-23.86 Million | -3.991x | -331.75% |
| 2023-12-31 | $26.07 Million | $-24.10 Million | -0.924x | -74.55% |
| 2022-12-31 | $52.19 Million | $-27.64 Million | -0.530x | -120.74% |
| 2021-12-31 | $78.99 Million | $-18.95 Million | -0.240x | +75.85% |
| 2020-12-31 | $17.89 Million | $-17.77 Million | -0.993x | +10.06% |
| 2019-12-31 | $15.57 Million | $-17.20 Million | -1.104x | -29.18% |
| 2018-12-31 | $14.27 Million | $-12.20 Million | -0.855x | -99.84% |
| 2017-12-31 | $17.12 Million | $-7.32 Million | -0.428x | -70.01% |
| 2016-12-31 | $14.96 Million | $-3.76 Million | -0.252x | -144.25% |
| 2015-12-31 | $-744.70K | $-423.51K | 0.569x | -- |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more